Thermo Fisher Scientific's $13.6 Billion Acquisition of Life Technologies Boosts Flagging M&A Numbers May 01, 2013 | Press Release
Burrill Securities Launches Institutional Breakthrough Series April 29, 2013 | Press Release
Big Biotech Outpaces Big Pharma, Burrill & Company says April 16, 2013 | Press ReleaseSee all News
Wenyong WangManaging Director
Wenyong Wang joined Burrill & Company in 2011 and has more than 18 years experience in the healthcare industry. Prior to joining Burrill Merchant Banking, Dr. Wang was a senior executive member of Boenning & Scattergood Global Healthcare Investment Banking practice, where he initiated and led Merger & Acquisition, licensing & partnering, capital raising, fairness opinions, as well as other financial and scientific advisory activities in public and private life sciences companies. He had managed over 25 public offerings and private placements, as well as M&A assignments ranging from $5 million to $500 million, in an aggregated value of over two billion dollars. Dr. Wang’s prior Investment Banking experience was with Janney Montgomery Scott in Philadelphia as a vice president. With Janney, Dr. Wang and his team provided investment banking services to public and private healthcare clients throughout Asian Pacific, Europe and North America. Prior to Janney, Dr. Wang worked on drug research and development at GlaxoSmithKline for more than six years. At GSK, he oversaw two drug candidates selected to clinical trials. Previously, Dr. Wang conducted independent research at the University of Pennsylvania and in Beijing, China.
Dr. Wang received his Ph.D. in Organic Chemistry from the University of Pennsylvania, his BS from Shandong University, and his MBA from Penn State.